Showing 11-18 of 18 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| Targeted mRNA LNP strategies to modulate lymphocyte migration and Treg function for T1D immunotherapy | Trustees of the University of Pennsylvania | Michael Betts | Cures | 01-September-2024 to 31-August-2027 | $900,000.00 |
| Mapping islet-reactive T cell responses by islet cell co-culture | Trustees of the University of Pennsylvania | Michael Betts | Cures | 01-July-2022 to 30-June-2025 | $825,000.00 |
| T1 TRIDENT / Transformative Research in Diabetic Nephropathy | Trustees of the University of Pennsylvania | Katalin Susztak | Improving Lives | 01-September-2019 to 30-September-2024 | $191,795.06 |
| An AI-driven bioelectronics system to accelerate SC-islet maturation | Trustees of the University of Pennsylvania | Juan Alvarez | Cures | 01-April-2025 to 31-March-2026 | $200,000.00 |
| Evaluating gene-modified hypo-immune PSCs for immune evasion in NHPs | Trustees of the University of Pennsylvania | Ji Lei | Cures | 01-June-2025 to 31-May-2027 | $749,999.08 |
| Pancreatic Lymph Node T cell Composition and Function in Human Type 1 Diabetes | Trustees of the University of Pennsylvania | Gregory Golden | Cures | 01-April-2023 to 31-March-2026 | $214,356.00 |
| Dock2-mediated T cell migration as a targetable shared mechanism in autoimmunity | University of Pittsburgh | Alok Joglekar | Cures | 01-September-2025 to 31-August-2026 | $149,999.05 |
| Defining the Antigenic Landscape of Islet-Infiltrating T cells in Type 1 Diabetes | University of Pittsburgh | Alok Joglekar | Cures | 01-March-2023 to 28-February-2026 | $900,000.00 |